Vertex Pharmaceuticals (VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion ...
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for. Vertex Pharmaceuticals beat analysts’ revenue expectations by 3.2% ...
Vertex Pharmaceuticals has a 1-year low of $377.85 and a 1-year high of $519.88. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01.
Vertex Pharmaceuticals has a 1 year low of $377.85 and a 1 year high of $519.88. The firm’s fifty day simple moving average is $435.91 and its 200 day simple moving average is $461.85.
Vertex Pharmaceuticals Incorporated VRTX reported mixed results for its fourth quarter on Monday. The company posted quarterly adjusted earnings of $3.48 per share which missed the analyst ...
Piper Sandler analyst Christopher Raymond maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $533.00. The company’s shares closed ...
Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex Pharmaceuticals (NASDAQ:VRTX) revealed 10 unusual trades. Delving into ...
Cantor Fitzgerald analyst Olivia Brayer maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target of $480.00. The company’s shares closed ...
Vertex Pharmaceuticals recently obtained approval for its non-opioid pain medication. The drug could become a blockbuster and a key part of Vertex's portfolio. The stock has been rising in value ...
Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed both its biotech peers and the broader market since 2022. The company dominates the cystic fibrosis market and is ...
Analysts' ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) over the last quarter vary from bullish to bearish, as provided by 21 analysts. Summarizing their recent assessments, the table below ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results